Biogen Shares Fall 4% as Weak Outlook Overshadows Q4 Earnings Beat

Biogen (NASDAQ:BIIB) is a biotechnology company known for its focus on neurological diseases. It develops therapies for conditions like multiple sclerosis and spinal muscular atrophy. Biogen faces competition from other biotech firms such as Roche and Novartis. On May 5, 2025, H.C. Wainwright maintained its "Buy" rating for Biogen, with the stock trading at $123.53.

Biogen's first-quarter 2025 results were mixed. The company reported adjusted earnings per share (EPS) of $3.02, which fell short of the Zacks Consensus Estimate of $3.32. This represents an 18% decline in earnings year over year. The shortfall is mainly due to a $165 million upfront payment to Stoke Therapeutics for a collaboration on zorevunersen, a treatment for Dravet syndrome.

Despite the earnings miss, Biogen's total revenues for the quarter reached $2.43 billion. This marks a 6% increase year over year on a reported basis and an 8% increase on a constant-currency basis. The revenue growth was driven by higher sales from new drugs, which helped offset declines in sales of key multiple sclerosis drugs like Tecfidera and Tysabri.

Sales of Spinraza, a spinal muscular atrophy drug, showed slight improvement, contributing to the revenue growth. However, Biogen has lowered its EPS guidance for the current year, indicating potential challenges ahead. The current stock price of BIIB is $122.45, reflecting a decrease of 0.87% with a change of $1.08.

The stock has fluctuated between a low of $122.18 and a high of $123.43 during the day. Over the past year, BIIB has reached a high of $238 and a low of $110.04. The company's market capitalization stands at approximately $17.94 billion, with a trading volume of 176,744 shares on the NASDAQ today.

• Biogen Inc. (NASDAQ:BIIB) reported mixed financial results for the first quarter of 2025, with an adjusted EPS of $3.02, missing the Zacks Consensus Estimate.
• The company's total revenues reached $2.43 billion, marking a 6% increase year over year, driven by higher sales from new drugs.
• Biogen's market position and future prospects are under scrutiny, with its stock price currently at $122.81, reflecting a decrease of 0.58%.

Biogen Inc. (NASDAQ:BIIB) is a leading biotechnology company known for its focus on neurological diseases, developing therapies for conditions like multiple sclerosis and spinal muscular atrophy. Despite facing stiff competition from other biotech giants such as Roche and Novartis, Biogen continues to strive for innovation in its field. Recently, Andrew Fein from H.C. Wainwright set a price target of $187 for Biogen, suggesting a potential upside of 52.77% from its current trading price of $122.41.

In the first quarter of 2025, Biogen reported mixed financial results. The company's adjusted earnings per share (EPS) was $3.02, which fell short of the Zacks Consensus Estimate of $3.32. This represents an 18% decline in earnings year over year. The shortfall is mainly attributed to a $165 million upfront payment to Stoke Therapeutics for a collaboration on zorevunersen, a treatment for Dravet syndrome.

Despite the earnings miss, Biogen's total revenues for the quarter reached $2.43 billion, marking a 6% increase year over year on a reported basis and an 8% increase on a constant-currency basis. This growth was driven by higher sales from new drugs, which helped offset declines in sales of key multiple sclerosis drugs like Tecfidera and Tysabri. Sales of Spinraza, a spinal muscular atrophy drug, also showed slight improvement.

Biogen's current market position is under scrutiny, as highlighted by Seeking Alpha. Investors are questioning whether the company is a value trap or on the brink of a significant turnaround. The analysis suggests that stakeholders are closely monitoring Biogen's strategic moves and financial health to determine if the company can overcome its challenges and achieve a successful turnaround.

The stock price of BIIB is currently $122.81, reflecting a decrease of 0.58% or $0.72. Over the past year, the stock has fluctuated between a high of $238 and a low of $110.04. With a market capitalization of approximately $17.99 billion, Biogen's upcoming earnings report, scheduled for May 1, 2025, is crucial. If the actual earnings surpass current estimates, the stock might see an upward movement. Conversely, a miss could lead to a decline in the stock's value.

Biogen (NASDAQ:BIIB) is a biotechnology company known for its focus on neurological diseases. It develops therapies for conditions like multiple sclerosis and spinal muscular atrophy. Biogen faces competition from other biotech firms such as Roche and Novartis. On May 5, 2025, H.C. Wainwright maintained its "Buy" rating for Biogen, with the stock trading at $123.53.

Biogen's first-quarter 2025 results were mixed. The company reported adjusted earnings per share (EPS) of $3.02, which fell short of the Zacks Consensus Estimate of $3.32. This represents an 18% decline in earnings year over year. The shortfall is mainly due to a $165 million upfront payment to Stoke Therapeutics for a collaboration on zorevunersen, a treatment for Dravet syndrome.

Despite the earnings miss, Biogen's total revenues for the quarter reached $2.43 billion. This marks a 6% increase year over year on a reported basis and an 8% increase on a constant-currency basis. The revenue growth was driven by higher sales from new drugs, which helped offset declines in sales of key multiple sclerosis drugs like Tecfidera and Tysabri.

Sales of Spinraza, a spinal muscular atrophy drug, showed slight improvement, contributing to the revenue growth. However, Biogen has lowered its EPS guidance for the current year, indicating potential challenges ahead. The current stock price of BIIB is $122.45, reflecting a decrease of 0.87% with a change of $1.08.

The stock has fluctuated between a low of $122.18 and a high of $123.43 during the day. Over the past year, BIIB has reached a high of $238 and a low of $110.04. The company's market capitalization stands at approximately $17.94 billion, with a trading volume of 176,744 shares on the NASDAQ today.

• Biogen Inc. (NASDAQ:BIIB) reported mixed financial results for the first quarter of 2025, with an adjusted EPS of $3.02, missing the Zacks Consensus Estimate.
• The company's total revenues reached $2.43 billion, marking a 6% increase year over year, driven by higher sales from new drugs.
• Biogen's market position and future prospects are under scrutiny, with its stock price currently at $122.81, reflecting a decrease of 0.58%.

Biogen Inc. (NASDAQ:BIIB) is a leading biotechnology company known for its focus on neurological diseases, developing therapies for conditions like multiple sclerosis and spinal muscular atrophy. Despite facing stiff competition from other biotech giants such as Roche and Novartis, Biogen continues to strive for innovation in its field. Recently, Andrew Fein from H.C. Wainwright set a price target of $187 for Biogen, suggesting a potential upside of 52.77% from its current trading price of $122.41.

In the first quarter of 2025, Biogen reported mixed financial results. The company's adjusted earnings per share (EPS) was $3.02, which fell short of the Zacks Consensus Estimate of $3.32. This represents an 18% decline in earnings year over year. The shortfall is mainly attributed to a $165 million upfront payment to Stoke Therapeutics for a collaboration on zorevunersen, a treatment for Dravet syndrome.

Despite the earnings miss, Biogen's total revenues for the quarter reached $2.43 billion, marking a 6% increase year over year on a reported basis and an 8% increase on a constant-currency basis. This growth was driven by higher sales from new drugs, which helped offset declines in sales of key multiple sclerosis drugs like Tecfidera and Tysabri. Sales of Spinraza, a spinal muscular atrophy drug, also showed slight improvement.

Biogen's current market position is under scrutiny, as highlighted by Seeking Alpha. Investors are questioning whether the company is a value trap or on the brink of a significant turnaround. The analysis suggests that stakeholders are closely monitoring Biogen's strategic moves and financial health to determine if the company can overcome its challenges and achieve a successful turnaround.

The stock price of BIIB is currently $122.81, reflecting a decrease of 0.58% or $0.72. Over the past year, the stock has fluctuated between a high of $238 and a low of $110.04. With a market capitalization of approximately $17.99 billion, Biogen's upcoming earnings report, scheduled for May 1, 2025, is crucial. If the actual earnings surpass current estimates, the stock might see an upward movement. Conversely, a miss could lead to a decline in the stock's value.

• Sumant Kulkarni from Canaccord Genuity sets a price target of $265 for Biogen Inc. (NASDAQ:BIIB), indicating a potential increase of about 91.95%.
• Biogen reports strong fourth-quarter earnings with an adjusted EPS of $3.44, surpassing consensus estimates.
• Despite positive earnings, revenue from multiple sclerosis products declined by 8%, with a notable decrease in sales of Tysabri.

On February 13, 2025, Sumant Kulkarni from Canaccord Genuity set a price target of $265 for Biogen Inc. (NASDAQ:BIIB). At the time, the stock was priced at $138.06, suggesting a potential increase of about 91.95%. Biogen, a biotechnology company, focuses on discovering, developing, and delivering therapies for neurological diseases. It competes with companies like Roche and Novartis.

Biogen recently reported strong fourth-quarter earnings, with an adjusted earnings per share (EPS) of $3.44, a 17% increase, surpassing the consensus estimate of $3.35. The company achieved sales of $2.46 billion, a 2% year-over-year increase on a constant currency basis and a 3% increase on a reported basis, exceeding the expected $2.40 billion. This performance highlights Biogen's ability to exceed market expectations.

Despite the positive earnings, Biogen's revenue from multiple sclerosis products declined by 8% to $1.07 billion. Sales of its multiple sclerosis drug, Tysabri, fell to $415.4 million from $464.7 million. This decline in a key revenue stream is a concern for investors, as it impacts the company's overall financial health.

Looking ahead, Biogen anticipates a full-year 2025 adjusted EPS between $15.25 and $16.25, which is below the consensus of $16.34. The company expects revenue to decline by a mid-single-digit percentage in 2025 compared to 2024. This is due to further decreases in multiple sclerosis product revenues, partially offset by new product launches.

Following the earnings announcement, Biogen's shares fell by 4.3%, closing at $133.43. Despite this, the stock has since increased to $138.55, reflecting a 3.84% rise. The stock's trading volume reached 1,225,466 shares, with a market capitalization of approximately $20.19 billion. Sumant Kulkarni maintains a Buy rating on the stock, indicating confidence in its future potential.

• Sumant Kulkarni from Canaccord Genuity sets a price target of $265 for Biogen Inc. (NASDAQ:BIIB), indicating a potential increase of about 91.95%.
• Biogen reports strong fourth-quarter earnings with an adjusted EPS of $3.44, surpassing consensus estimates.
• Despite positive earnings, revenue from multiple sclerosis products declined by 8%, with a notable decrease in sales of Tysabri.

On February 13, 2025, Sumant Kulkarni from Canaccord Genuity set a price target of $265 for Biogen Inc. (NASDAQ:BIIB). At the time, the stock was priced at $138.06, suggesting a potential increase of about 91.95%. Biogen, a biotechnology company, focuses on discovering, developing, and delivering therapies for neurological diseases. It competes with companies like Roche and Novartis.

Biogen recently reported strong fourth-quarter earnings, with an adjusted earnings per share (EPS) of $3.44, a 17% increase, surpassing the consensus estimate of $3.35. The company achieved sales of $2.46 billion, a 2% year-over-year increase on a constant currency basis and a 3% increase on a reported basis, exceeding the expected $2.40 billion. This performance highlights Biogen's ability to exceed market expectations.

Despite the positive earnings, Biogen's revenue from multiple sclerosis products declined by 8% to $1.07 billion. Sales of its multiple sclerosis drug, Tysabri, fell to $415.4 million from $464.7 million. This decline in a key revenue stream is a concern for investors, as it impacts the company's overall financial health.

Looking ahead, Biogen anticipates a full-year 2025 adjusted EPS between $15.25 and $16.25, which is below the consensus of $16.34. The company expects revenue to decline by a mid-single-digit percentage in 2025 compared to 2024. This is due to further decreases in multiple sclerosis product revenues, partially offset by new product launches.

Following the earnings announcement, Biogen's shares fell by 4.3%, closing at $133.43. Despite this, the stock has since increased to $138.55, reflecting a 3.84% rise. The stock's trading volume reached 1,225,466 shares, with a market capitalization of approximately $20.19 billion. Sumant Kulkarni maintains a Buy rating on the stock, indicating confidence in its future potential.